My Vendor Delisted Retatrutide — Here's What Actually Happened (and What to Do)

What happened

If you went to reorder retatrutide this week and found it missing, sold out, "discontinued," or just gone without a word, you're not the only one, and you didn't do anything wrong. Since Eli Lilly filed six federal lawsuits against a handful of named retatrutide sellers on August 12, 2026, some vendors have quietly pulled their own listings rather than wait to find out if they're next. We covered who Lilly actually sued and why the week it happened. This piece starts where that one left off, at the moment you're staring at an empty product page wondering what to do.

The first thing worth knowing is what a delisting is and isn't. It isn't a recall, nobody is telling you the vial you already have is unsafe, and nobody has banned retatrutide, because it was never approved for consumer sale in the first place, so there's nothing to un-approve. What changed is that individual companies decided their own risk tolerance had shifted, and they took their listings down. That's a handful of business decisions made in a handful of offices, not a market-wide event, and it's worth treating it as exactly that size.

Is retatrutide actually gone

It's also worth saying plainly that the four online sellers Lilly actually named, Astra Peptides, Legendary Peptides, Texas Peptides, and Lone Star Peptide, aren't vendors we've ever tracked or listed. If the seller you were buying from is one we cover, it was never one of the four companies this lawsuit is about. That doesn't mean every vendor we list is beyond scrutiny. It means the specific legal action making headlines this week isn't aimed at the sellers most of you were likely using.

Was your vendor cutting corners

Probably not, at least not because of this. Vendors listing retatrutide under a generic research code or a house product name instead of the word "retatrutide" itself is normal in this market and has been for a long time, it isn't a new trick to dodge a lawsuit. Pulling a listing after a competitor gets sued is a cautious call, and it's the kind a vendor with nothing to hide makes just as often as one that doesn't. It's a reasonable moment to check that vendor's certificate of analysis and reviews if you haven't recently, the way you'd check any vendor periodically, but a delisting by itself isn't evidence you were sold something bad.

What this means for you right now

If your usual source is gone, you have options, and you don't have to act on all of them today. Compare current per-mg pricing across the vendors still listing retatrutide before picking a new one, and use the vendor directory to actually read a certificate of analysis rather than just trusting the phrase "third-party tested." Our own price tracking already showed retatrutide's per-mg price falling through late July and into August, even as this pressure built, so there's no data-backed reason to rush into the first listing you find out of fear the price is about to spike. It hasn't, and the vendors still standing aren't scarce.

Enforcement in this market also tends to move one company at a time rather than shutting a compound down outright, something worth keeping in mind before you assume the whole supply is at risk. We saw a version of that pattern play out earlier this month with an unrelated vendor, whose owner was sentenced to federal prison while a similarly styled site appeared elsewhere soon after. That's not a reason to be careless. It's a reason to spend your caution on checking the new vendor's paperwork rather than on how fast you can find a replacement.

What to watch next is whether more vendors pull listings voluntarily over the coming weeks, and whether Lilly's push to cut off payment processors and platforms, the lever it's leaning on harder than the lawsuits themselves, actually sticks. Either one would move supply more than six lawsuits alone. We're tracking our own vendor and price data daily and we'll update this if the picture changes.